Cannabidiol Adverse Effects and Toxicity

Marilyn A Huestis, Renata Solimini, Simona Pichini, Roberta Pacifici, Jeremy Carlier, Francesco Paolo Busardò

Research output: Contribution to journalReview articlepeer-review

Abstract

BACKGROUND: Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD occurred in the 1970s and intensified recently with many discoveries about the endocannabinoid system. Multiple preclinical and clinical studies led to FDA-approval of Epidiolex®, a purified CBD medicine formulated for oral administration for the treatment of infantile refractory epileptic syndromes, by the US Food and Drug Administration in 2018. The World Health Organization considers rescheduling cannabis and cannabinoids. CBD use around the world is expanding for diseases that lack scientific evidence of the drug's efficacy. Preclinical and clinical studies also report adverse effects (AEs) and toxicity following CBD intake.

METHODS: Relevant studies reporting CBD's AEs or toxicity were identified from PubMed, Cochrane Central, and EMBASE through January 2019. Studies defining CBD's beneficial effects were included to provide balance in estimating risk/benefit.

RESULTS: CBD is not risk-free. In animals, CBD AEs included developmental toxicity, embryo-fetal mortality, central nervous system inhibition and neurotoxicity, hepatocellular injuries, spermatogenesis reduction, organ weight alterations, male reproductive system alterations, and hypotension, although at doses higher than recommended for human pharmacotherapies. Human CBD studies for epilepsy and psychiatric disorders reported CBD-induced drug-drug interactions, hepatic abnormalities, diarrhea, fatigue, vomiting, and somnolence.

CONCLUSION: CBD has proven therapeutic efficacy for serious conditions such as Dravet and Lennox-Gastaut syndromes and is likely to be recommended off label by physicians for other conditions. However, AEs and potential drug-drug interactions must be taken into consideration by clinicians prior to recommending off-label CBD.

Original languageEnglish
Pages (from-to)974-989
Number of pages16
JournalCurrent Neuropharmacology
Volume17
Issue number10
DOIs
Publication statusPublished - 2019

Keywords

  • Animals
  • Brain/drug effects
  • Cannabidiol/adverse effects
  • Cardiovascular System/drug effects
  • Gastrointestinal Tract/drug effects
  • Genitalia
  • Humans
  • Liver/drug effects
  • Respiratory System/drug effects

Fingerprint Dive into the research topics of 'Cannabidiol Adverse Effects and Toxicity'. Together they form a unique fingerprint.

Cite this